Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Testosterone Deficiency
FDA Approves Oral Testosterone Replacement Therapy Tlando
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Cardiovascular Events, VTE Tied to Polycythemia During Testosterone Therapy
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
e-ECE: Testosterone Therapy Mitigates NAFLD in Obese Men With FH, T2D
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
Testosterone Replacement May Benefit Younger Male Cancer Survivors
Benefits include significant improvement in body composition measurements over 6 months.
Testosterone Therapy Raises Risk of Venous Thromboembolism
Study reveals an approximately 2-fold increased odds of venous thromboembolism associated with testosterone therapy in men with or without hypogonadism
Position Statement Clarifies Benefits of Testosterone Therapy for Women
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Review Supports Testosterone for Low Sexual Desire in Women
Beneficial effects for postmenopausal women, with preference for nonoral testosterone administration
Testosterone Therapy Safe Despite Prostate Cancer
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
- Loading...
Loading...
Next post in AUA 2019 Coverage
Loading... 
Loading...